Umeda T, Naomi S, Inoue J, Ohno M, Miura F, Hamasaki S, Iwaoka T, Sato T
Clin Exp Hypertens A. 1987;9(7):1209-19. doi: 10.3109/10641968709160044.
The plasma levels of a sodium pump inhibitor (Na+ PI) were measured by a modified method of Hamlyn et al, using dog kidney Na+, K+-ATPase. When the level of Na+ PI was expressed as the % inhibition of the enzyme and compared with that of a control solution, it was found to be 9.0 +/- 0.7% in 43 untreated patients with essential hypertension. This was significantly higher than 5.0 +/- 0.4% for 56 normotensive subjects (p less than 0.01). Male patients with essential hypertension showed the highest mean value of 10.5 +/- 1.1%, disclosing an apparent sex difference in the patient group (p less than 0.01). Only in female patients was there a significant positive correlation between the inhibitor's level and the mean blood pressure (r = 0.649, p less than 0.01). These results provided additional evidence for increased Na+ PI in the plasma of patients with essential hypertension, which might bear an important role in the pathogenesis of the disease.
采用改良的哈姆林等人的方法，利用犬肾钠钾ATP酶来测定钠泵抑制剂（Na+ PI）的血浆水平。当将Na+ PI的水平表示为酶抑制百分比并与对照溶液进行比较时，发现43例未经治疗的原发性高血压患者的该水平为9.0±0.7%。这显著高于56例血压正常受试者的5.0±0.4%（p<0.01）。原发性高血压男性患者的平均值最高，为10.5±1.1%，表明患者组存在明显的性别差异（p<0.01）。仅在女性患者中，抑制剂水平与平均血压之间存在显著正相关（r = 0.649，p<0.01）。这些结果为原发性高血压患者血浆中Na+ PI升高提供了额外证据，这可能在该疾病的发病机制中起重要作用。
